Observational studyActa cardiologica2025

Determinants of lipid lowering therapy intensification in very high risk patients with dyslipidaemia eligible for PCSK9 monoclonal antibodies: 1-year outcomes of the PERI-DYS study.

Klaus G Parhofer et al.PubMed ↗Publisher ↗

No baseline ezetimibelooks good hereLower LLT intensification.Correlation only, not a test of it.
Statin intolerancelooks good hereLower LLT intensification.Correlation only, not a test of it.

What moved togetherboth groups pooled, not the treatment’s effect

Correlation, not cause

No baseline ezetimibe went with lower LLT intensification

−57%

no baseline ezetimibe vs baseline ezetimibe

Bigger than 9 in 10 on the map

As reported

OR 0.43, no interval

Correlation, not cause

Statin intolerance went with lower LLT intensification

−32%

statin intolerance vs no statin intolerance

Bigger than 7 in 10 on the map

As reported

OR 0.68, no interval

Who was studied, and how

1,695people in the Prospective German Very High Cardiovascular Risk Patients Dyslipidemia Treatment Indication Registry trial, from 2017

1,565of them with cardiovascular disease, in this paper

Already taking no baseline ezetimibe, or nottheir own situation, not assigned

on no baseline ezetimibe

baseline ezetimibe

No baseline ezetimibe went with lower LLT intensification−57%

correlation, not a test

Already taking statin intolerance, or nottheir own situation, not assigned

on statin intolerance

not on statin intolerance

Statin intolerance went with lower LLT intensification−32%

correlation, not a test

the abstract, start to end

… years 0.73), no baseline ezetimibe (OR 0.43), LDL-C > 100 mg/dL (OR 3.90), and statin intolerance (OR 0.68).

← favours treatmentfavours comparator →

could be chance

No interval given · direction only, strength unknown

LLT intensificationno baseline ezetimibe vs baseline ezetimibe

OR 0.43

LLT intensificationstatin intolerance vs no statin intolerance

OR 0.68

StatinsOther lipid agentsLipids

1 / 4

1 paper cites it

2025

2026

this papercites it

The trial

NCT031104321,695 enrolled2017